<DOC>
	<DOC>NCT00693485</DOC>
	<brief_summary>A multicenter, randomized, patient-masked, sham-controlled evaluation of the safety and effects on visual function of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy. Patients will be followed for up to 1 year.</brief_summary>
	<brief_title>Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>Primary openangle glaucoma in one eye Visual acuity 20/80 or better Intraocular pressure in the study eye â‰¤ 24 mm Hg Glaucomatous visual field loss 7 dB to 25 dB Known allergy to brimonidine tartrate Uncontrolled systemic disease or infection of the eye Recent eye surgery or injections in the eye Female patients who are pregnant, nursing or planning a pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>